Trials / Completed
CompletedNCT01312831
Efficacy and Safety Study of Oral Eligen® B12 in Subjects With Low Serum Cobalamin
A 60-DAY, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Eligen® B12 OR Intramuscularly Administered B12 in Subjects With Low Serum Cobalamin With a 30 Day Extension to 90 Days of Dosing
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Emisphere Technologies, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy and safety profile of a new oral vitamin B12 formulation (Eligen® B12) with intramuscular B12 in restoring normal B12 (cobalamin) concentrations in subjects with low cobalamin levels (\<350 pg/mL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Vitamin B12 (cyanocobalamin) |
Timeline
- Start date
- 2009-02-01
- Completion
- 2010-12-01
- First posted
- 2011-03-11
- Last updated
- 2011-03-11
Source: ClinicalTrials.gov record NCT01312831. Inclusion in this directory is not an endorsement.